Eloxx reports Q2 2026 results after $66 million raise and Nasdaq uplisting
The company plans to start a Phase 2b Alport syndrome trial in Q3 2026 and holds $62 million in cash it says will fund operations into mid-2028.
SEC filing
Latest
1 story
Sign in